All News

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

Johnson & Johnson's posdinemab aims to slow tau pathology in early and preclinical Alzheimer’s disease populations.

Your daily dose of the clinical news you may have missed.

Significant strides were made in 2024 in evaluating a wide range of treatments for migraine, including phase 2 findings with PACAP inhibition, PI McAllister said.

The updated guidelines include 19 recommendations related to the diagnosis and management of eosinophilic esophagitis.

The bird flu threat remains low, according to public health authorities, but awareness and vigilance will help keep it that way. Here are 9 things you need to know.

The first death of an American from the H5N1 virus was reported in Louisiana on Monday, though authorities maintain the risk of widespread infection remains low.

Your daily dose of the clinical news you may have missed.

The onset of migraine with its wide range of symptoms may be telegraphed as early as 2 days before by the frequency of neuronal oscillation deep in the brain.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

The 2025 rankings released by U.S. News & World Report featured 13 new diets and 12 new categories.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

Your daily dose of the clinical news you may have missed.

Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.

Murthy's advisory outlines evidence for the cancer-alcohol relationship and calls for greater efforts to increase public awareness of the risks from beer, wine, and spirits.

The USPSTF's revised CRC screening guidelines to include adults aged 45-49 years increased screening needs by about 23% without additional funding or resources for CHCs.

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.